Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer

Kevin Kalinsky, Katherine D. Crew, Susan Refice, Tong Xiao, Antai Wang, Sheldon M. Feldman, Bret Taback, Aqeel Ahmad, Serge Cremers, Hanina Hibshoosh, Matthew Maurer, Dawn L. Hershman

Research output: Contribution to journalArticle

46 Scopus citations

Abstract

Introduction: We conducted a presurgical trial to assess the tissue-related effects of metformin in overweight/obese breast cancer (BC) patients. Methods: Metformin 1,500 mg daily was administered to 35 nondiabetics with stage 0-III BC, body mass index (BMI) ≥ 25 kg/m2. The primary endpoint was tumor proliferation change (i.e., ki-67). Tumor proliferation change was compared to untreated historical controls, matched by age, BMI, and stage. Results: There was no reduction in ln(ki-67) after metformin (p = .98) or compared to controls (p = .47). There was a significant reduction in BMI, cholesterol, and leptin. Conclusion: Despite no proliferation changes, we observed reductions in other relevant biomarkers.

Original languageEnglish (US)
Pages (from-to)150-157
Number of pages8
JournalCancer Investigation
Volume32
Issue number4
DOIs
StatePublished - Apr 2014
Externally publishedYes

Keywords

  • Breast cancer
  • Hispanic
  • Insulin resistance
  • Ki-67
  • Metformin
  • Presurgical

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer'. Together they form a unique fingerprint.

  • Cite this

    Kalinsky, K., Crew, K. D., Refice, S., Xiao, T., Wang, A., Feldman, S. M., Taback, B., Ahmad, A., Cremers, S., Hibshoosh, H., Maurer, M., & Hershman, D. L. (2014). Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer. Cancer Investigation, 32(4), 150-157. https://doi.org/10.3109/07357907.2014.889706